Drug Profile
Research programme: rod-derived cone viability factor therapeutics - Fovea Pharmaceuticals
Alternative Names: FOV 2501Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator INSERM; Novartis
- Developer Fovea Pharmaceuticals
- Class Proteins
- Mechanism of Action TXNL6 protein agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - Eye disorders
Highest Development Phases
- No development reported Retinitis pigmentosa
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Retinitis-pigmentosa in France (Intravitreous)
- 14 Jul 2010 Preclinical development is ongoing in France
- 14 Jul 2010 Recombinant human rod-derived cone viability factor is available for licensing worldwide (http://www.fovea-pharma.com)